2023 World Conference on Lung Cancer (Posters)-EP11.04. Increasing Liquid Biopsy Sensitivity to the Next Level: Usability of Minimal Residual Disease Detection of Genomic Fusions by ddPCR

EP11.04. Increasing Liquid Biopsy Sensitivity to the Next Level: Usability of Minimal Residual Disease Detection of Genomic Fusions by ddPCR - PDF(Abstract)

Back to course

Pdf Summary

This document provides an overview of a presentation titled "Increasing liquid biopsy sensitivity to the next level: Usability of minimal residual disease detection of genomic fusions by ddPCR" that will be presented at the WCLC 2023 conference. The presentation focuses on the use of liquid biopsy in the detection of genomic fusions in non-small cell lung cancer (NSCLC) patients. Liquid biopsy has the potential to be used for therapy monitoring and to inform optimal therapy in both the metastatic and non-metastatic curative setting. However, the sensitivity of current ctDNA assays is limited, especially in the non-metastatic setting.<br /><br />The authors plan to investigate the usability of generating breakpoint specific ddPCR primers in 40 NSCLC stage IV patients treated with immune checkpoint inhibitors and/or chemotherapy. These primers are derived from tumor specific genomic breakpoints and will be tested at different time points during the course of 1st line treatment. The correlation of ddPCR minimal residual disease (MRD) monitoring results with overall response rate, progression-free survival, and overall survival will be analyzed. This study is part of the Thera-Sure CNI-Monitor Trial conducted by the CCC-N University of Göttingen, MHH.<br /><br />The presentation will be part of the "Metastatic Non-small Cell Lung Cancer - Immunotherapy" track at the conference. The keywords associated with the presentation include liquid biopsy, NSCLC, and immune-therapy. The abstract type is "Clinical Trials in Progress". The trial is expected to start recruiting in June 2023 and will have a recruitment period of 15 months and a follow-up period of 18 months.

Asset Subtitle

Frank Griesinger

Meta Tag

Speaker Frank Griesinger

Topic Metastatic NSCLC: Immunotherapy - TIPs

Keywords

liquid biopsy

NSCLC

genomic fusions

ddPCR

therapy monitoring

ctDNA assays

immune checkpoint inhibitors

chemotherapy

minimal residual disease (MRD) monitoring

Clinical Trials in Progress